Continuous Glucose Monitoring Devices Market Overview

The continuous glucose monitoring devices market growth is anticipated from 2025 to 2035, driven by increase in prevalence of diabetes due to unhealthy lifestyle. By 2025, the market is projected to reach a value of around USD 6.1 Billion. Looking ahead to 2035, it is expected to expand further to about USD 18.3 Billion. This represents an annual growth rate of 10.6% over the ten-year period.

Continuous glucose monitoring (CGM) refers to using a device that automatically calculates your blood glucose level, also known as your blood sugar, during the day and at night. Continuous glucose monitoring, or CGM, is wearable technology that monitors your glucose, or sugar, levels over a period of time. It takes the glucose level in the fluid beneath your skin 24 hours a day when you wear the device. Others also refer to it as a continuous glucose monitor, or a CGM.

A CGM system is basically a diabetes aid for the person with diabetes. Diabetes is all about managing your glucose levels in the blood. A CGM gives you constant feedback on the fluctuation in your glucose levels. Different kinds of CGM devices exist, and the technology keeps changing fast. Diabetes data and information reflect the rising burden on the individual, families, and the country. As per the IDF Diabetes Atlas (2021), 10.5% of adults aged 20-79 years live with diabetes, with almost half not realizing that they live with the condition. IDF projections by the year 2045 reflect that 1 in 8 adults, approximately 783 million, will live with diabetes, an increase of 46%.

Continuous Glucose Monitoring Devices Market Drivers and Opportunities

Rising Prevalence of Diabetes and Growing Awareness of Diabetes Management

Increasing prevalence of diabetes all over the world is the major growth driver for the Continuous Glucose Monitoring (CGM) devices market. According to the International Diabetes Federation (IDF), over 537 million adults had diabetes in 2021, and the number is expected to rise to 783 million by the year 2045. Aging populations, sedentary lifestyles, obesity, and unhealthful diets are the causes for this rapid growth.

Real-time glucose monitoring using CGM devices allows diabetes patients to attain better glycemic control when compared to traditional self-monitoring blood glucose (SMBG). Unlike the snapshot provided by traditional fingerstick testing at a single point in time, CGM provides continuous data and trend information, enabling more informed decision-making for patients as well as healthcare professionals. Furthermore, governments as well as healthcare institutions are actively promoting awareness programs and reimbursement policies, boosting the uptake of CGM.

Technological Advancements and Integration with Digital Health Solutions anticipated to drive global Continuous Glucose Monitoring Devices Market size

The rapid pace of CGM technology advancements has greatly increased their accuracy, convenience, and connectivity. New CGM devices, such as Dexcom G7, Abbott’s FreeStyle Libre 3, and Medtronic’s Guardian Connect, come with longer wear periods, better accuracy, and more comfortable, smaller designs.

Another major advancement has been the integration of CGM devices with smartphones, cloud platforms, and insulin delivery systems. Bluetooth connectivity and smartphone applications that provide real-time monitoring of glucose levels are standard with most CGMs. CGMs are increasingly being integrated in artificial pancreas systems, where the CGM collaborates with automated insulin pumps to create a closed system for proper diabetes control. AI-predictive analytics usage further enhances the efficiency of CGM by providing the individual with advance alerts regarding probable glucose spikes even before their occurrence.

Opportunity for the Continuous Glucose Monitoring Devices Market growth

Expansion into Non-Diabetic and Preventive Healthcare Applications

One of the most promising growth opportunities for CGM devices exists in their expansion beyond the traditional diabetes care market to the area of preventive healthcare and non-diabetic applications. As the area of personalized medicine and monitoring through digital health continues to expand, CGM technology is increasingly being researched for monitoring metabolic health, weight, optimization of physical fitness, and detection of prediabetes.

Companies like Dexcom, Abbott, and Levels Health are attempting to make CGMs more accessible to non-diabetic individuals who want to track their glucose response to food, exercise, and stress levels. This trend is increasingly popular with athletes, biohackers, and those concerned with metabolic health.

Moreover, healthcare professionals are increasingly recognizing CGM as a valuable instrument for the detection and intervention in those at risk for Type 2 diabetes. Since CGM tracks glucose trends over an extended duration, the devices aid the user in recognizing diet and lifestyle adjustments that may prevent the disease from progressing. Growth in the use of wearable medical device technology, rising consumer demand for real-time health data, and corporate wellness programs are also driving the market opportunity.

Continuous Glucose Monitoring Devices Market Scope

Continuous Glucose Monitoring Devices Market Report Segmentation Analysis

The Global continuous glucose monitoring devices market report analysis is segmented into by Component, by technology, by age group, by type of diabetes, by distribution channel and by region.

The Sensors component segment dominated the market in 2024 and is predicted to grow at the highest CAGR over the forecast period.

Sensors are the fastest-growing segment in the Continuous Glucose Monitoring (CGM) market, followed by transmitters & receivers and integrated insulin pumps. Continuous glucose monitoring market growth is largely driven by the normal change cycle of CGM sensors, which must be replaced every 7 to 14 days, creating constant demand. Technological advancement in the accuracy, durability, and comfort provided by sensors has also increased their popularity, further propelling growth.

The increasing popularity of wearable CGM devices has also contributed to increased usage of sensors as more and more individuals, including non-diabetics, are using CGM technology for health monitoring on a preventive level. Integrated insulin pumps are increasing in the market, but their usage is still limited to patients with Type 1 diabetes that require automated delivery of insulin. Transmitters & receivers, on the other hand, are experiencing slower growth as new models integrate these functions with all-in-one, more streamlined systems. As the demand for real-time, non-invasive glucose monitoring increases, the sensors segment shall remain the market driver in the years to come.

The Wearable CGM technology systems segment is predicted to grow at the highest CAGR over the forecast period.

The wearable Continuous Glucose Monitoring (CGM) technology systems segment is projected to grow with the highest compound annual growth rate (CAGR) throughout the forecasting period. This growth stems from increasing demand for real-time, non-invasive glucose monitoring solutions that are easy to use and accurate for diabetes management.

Wearable CGM systems, such as Abbott’s FreeStyle Libre, Dexcom’s G-Series, and Medtronic’s Guardian Connect, are gaining popularity as they provide continuous glucose monitoring without the necessity for repeated fingerstick testing. In addition, Technological advancements, such as longer wear, higher accuracy, and smartphone and insulin pump compatibility, are also accelerating the trend. Additionally, the heightened emphasis on remote monitoring and digital health solutions is also turning wearable CGMs into the preferred solution for healthcare professionals as well as patients.

The following segments are part of an in-depth analysis of the global continuous glucose monitoring devices market outlook:

Continuous Glucose Monitoring Devices Market Share Analysis by Region

North America is projected to hold the largest share of the global Continuous Glucose Monitoring Devices Market growth over the forecast period.

North America leads the Continuous Glucose Monitoring (CGM) devices market because of a high prevalence of diabetes, a well-established healthcare system, and strong insurance coverages. The presence of leading industry players, such as Dexcom, Abbott, and Medtronic, has stimulated innovation, making the CGM devices more accessible and popular. Additionally, government programs and increased awareness regarding the management of diabetes have also led to the leadership of North America in the market. According to the American Diabetes Associations, In 2021, approximately 38.4 million Americans, or 11.6% of the American population, had diabetes, with 29.7 million having the condition and 8.7 million undiagnosed. Data on the use of CGM are scant, but approximately 2 million people with diabetes in the United States use continuous glucose monitors, and the figure has doubled since the year 2019.

Meanwhile, the Asia-Pacific (APAC) region remains the most dynamic, spearheaded by the expansion of the diabetic patient base in China, India, and Japan. Increased accessibility to healthcare, increasing investments in medical technology, and government policies supporting the growth are accelerating the adoption of CGM. Furthermore, collaborations with local and international CGM manufacturers are driving the growth in the market, with APAC being the growth region for the future.

Continuous Glucose Monitoring Devices Market Competition Landscape Analysis

The continuous glucose monitoring devices is competitive, with several established players and new entrants offering a range of continuous glucose monitoring devices products. Some of the key players include Dexcom, Inc., Abbott Laboratories, Medtronic plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd,  Ascensia Diabetes Care, LifeScan, Inc. and others.

Global Continuous Glucose Monitoring Devices Market Recent Developments News:

o   In December 2024, Abbott and Dexcom resolved all outstanding patent litigation on CGM devices. The agreement included dismissal of all outstanding legal action throughout the world and a mutual agreement not to pursue additional patent litigation against each other for the next decade.

o   In August 2024, Abbott and Medtronic, two leading medical device companies, entered a global collaboration to integrate Abbott's advanced FreeStyle Libre CGM technology with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The integration would adjust the insulin automatically based on the real-time glucose levels, thereby providing better glucose control for diabetic patients. The collaboration would provide more integrated and customized diabetes care solutions.

o   In May 2024, Senseonics Holdings, Inc., committed to the production and development of implantable, long-term continuous glucose monitor systems for patients with diabetes, in collaboration with its international commercial partner Ascensia Diabetes Care and St. Louis-based Mercy, a leading health care system and accountable care organization, announced a groundbreaking partnership in a diabetes population management initiative.

The Global continuous glucose monitoring devices market dominated by a few large companies, such as

·         Dexcom, Inc.

·         Abbott Laboratories

·         Medtronic plc

·         Senseonics Holdings, Inc.

·         F. Hoffmann-La Roche Ltd

·         Ascensia Diabetes Care

·         LifeScan, Inc.

·         GlySens Incorporated

·         Echo Therapeutics, Inc.

·         Nemaura Medical Inc.

·         Integrity Applications, Inc.

·         Biolinq, Inc.

·         PKVitality

·         Noviosense

·         EOFlow Co., Ltd.

·         Others